Clinical trial
Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular…
NCT00414206 · CoMentis, Industry · Terminated
Key facts
| NCT number | NCT00414206 |
|---|---|
| Title | Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD) |
| Official title | A Phase II Randomized, Double-Masked, Study Comparing the Safety and Efficacy of ATG003 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (NV-AMD) |
| Lead sponsor | CoMentis, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug |
| Interventions | Mecamylamine, Placebo |
| Enrollment | 343 |
| Start date | Mar 1, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Dec 21, 2006 |
| Last update posted | Nov 23, 2010 |
| Countries | Brazil, Czechia, Mexico, Poland, Russia, Ukraine |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: